Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00572182
Other study ID # CDR0000578114
Secondary ID U01CA081457PBTC-
Status Terminated
Phase Phase 1
First received December 11, 2007
Last updated March 2, 2012
Start date July 2008
Est. completion date February 2011

Study information

Verified date March 2012
Source Pediatric Brain Tumor Consortium
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

RATIONALE: MK0752 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I trial is studying the side effects and best dose of MK0752 in treating young patients with recurrent or refractory CNS cancer.


Description:

OBJECTIVES:

Primary

- To estimate the maximum tolerated dose (MTD) and recommended phase II dose of MK0752 administered for 3 consecutive days of every 7 days in 28 day courses to young patients with recurrent or refractory CNS malignancies (Dosing regimen 1 - closed to accrual 2/23/2010).

- To estimate the MTD and recommend a phase II dose of MK0752 administered once weekly in 28 day courses to young patients with recurrent or refractory CNS malignancies (Dosing regimen 2).

- To compared the MK0752 systemic exposure attained with each dosage level on the different dosing regimens.

Secondary

- To characterize the pharmacokinetics of MK0752.

- To document and describe toxicities associated with MK0752.

- To preliminarily define the antitumor activity of MK0752 within the confines of a phase I setting.

OUTLINE: This is a multicenter, dose-escalation study.

Patients receive oral MK0752 once daily on days 1-3, 8-10, 15-17, and 22-24 (dosing regimen 1 - closed to accrual 2/23/2010) or days 1, 8, 15, and 22 (dosing regimen 2). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Treatment may be extended up to 19 courses if the patient is benefitting from the treatment.

Patients undergo blood sample collection periodically for pharmacokinetic studies.

After completion of study treatment, patients are followed for 30 days.


Other known NCT identifiers
  • NCT00923208

Recruitment information / eligibility

Status Terminated
Enrollment 33
Est. completion date February 2011
Est. primary completion date February 2011
Accepts healthy volunteers No
Gender Both
Age group 3 Years to 21 Years
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed primary CNS tumor

- Patients with intrinsic brain stem tumors do not require histologic verification, but must have radiographic evidence of progression

- Recurrent disease or refractory to standard therapy

- No histologically benign brain tumors (e.g., low-grade glioma)

PATIENT CHARACTERISTICS:

- Karnofsky performance status (PS) or Lansky PS 60-100%

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Absolute neutrophil count = 1,000/µL

- Platelet count = 100,000/µL (unsupported)

- Hemoglobin = 8 g/dL (RBC transfusions allowed)

- Creatinine clearance OR glomerular filtration rate = 70 mL/min OR serum creatinine based on age as follows:

- 0.8 mg/dL (= 5 years of age)

- 1.0 mg/dL (> 5 to = 10 years of age)

- 1.2 mg/dL (> 10 to = 15 years of age)

- 1.5 mg/dL (> 15 years of age)

- Bilirubin = 1.5 times upper limit of normal (ULN) for age

- ALT = 2.5 times ULN for age

- Albumin = 2.5 g/dL

- Sodium, potassium, magnesium, and calcium normal

- Patients with neurological deficits are eligible provided these deficits are stable for = 2 weeks prior to study registration

- No clinically significant systemic illness (e.g., serious infection or significant cardiac, pulmonary, hepatic, or other organ dysfunction) that would compromise the patient's ability to tolerate study therapy or would likely interfere with the study procedures or results

- No known hypersensitivity to MK0752

PRIOR CONCURRENT THERAPY:

- Recovered from the acute toxic effects of all prior therapy

- At least 3 weeks since prior myelosuppressive anticancer chemotherapy (6 weeks for nitrosoureas)

- At least 7 days since prior investigational or biologic agents

- At least 3 weeks since prior investigational or biologic agents that have a prolonged half-life or for which the patient has experienced = grade 2 myelosuppression in the treatment course preceding discontinuation of therapy

- At least 3 half lives since prior monoclonal antibody therapy

- At least 6 months since prior total body irradiation or craniospinal radiotherapy

- At least 6 weeks since other prior substantial bone marrow irradiation

- At least 2 weeks since prior local palliative radiotherapy (small volume)

- At least 6 months since prior allogeneic bone marrow transplantation (BMT)

- No evidence of active graft versus host disease

- At least 3 months since prior autologous BMT or stem cell transplantation

- At least 7 days since prior hematopoietic growth factors (filgrastim [G-CSF], sargramostim [GM-CSF], or erythropoietin) (14 days for long-acting formulations)

- No prior MK0752

- No concurrent enzyme-inducing anticonvulsant drugs (EIACDs)

- No other concurrent anticancer or investigational drug therapy

- Concurrent dexamethasone allowed provided patient is on a stable or decreasing dose for = 2 weeks prior to study registration

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
MK-0752
This is a dose escalation study. Patients may receive 150, 200, 260 or 325 mg/m2 orally for 3 consecutive days of every 7 days for 28 days (dosing regimen 1 - closed to accrual 2/23/2010) or 800, 1000, 1400, or 1800 mg/m2 orally once weekly for 28 days (1 course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 6 courses.

Locations

Country Name City State
United States NCI - Pediatric Oncology Branch Bethesda Maryland
United States Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute Boston Massachusetts
United States Children's Memorial Hospital - Chicago Chicago Illinois
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States Duke Comprehensive Cancer Center Durham North Carolina
United States Dan L. Duncan Cancer Center at Baylor College of Medicine Houston Texas
United States St. Jude Children's Research Hospital Memphis Tennessee
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States Children's Hospital of Pittsburgh Pittsburgh Pennsylvania
United States UCSF Helen Diller Family Comprehensive Cancer Center San Francisco California
United States Seattle Children's Hospital Seattle Washington
United States Children's National Medical Center Washington District of Columbia

Sponsors (2)

Lead Sponsor Collaborator
Pediatric Brain Tumor Consortium National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose First 28 days of treatment Yes
Primary MK0752 systemic exposure Serial blood samples for pharmacokinetic studies of MK-0752 will be collected with the first dose of course 1 at pre-specified times. Day 1 of course 1 No
Secondary Pharmacokinetics Serial blood samples for pharmacokinetic studies of MK-0752 will be collected with the first dose of course 1 at pre-specified times. Day 1 of course 1 No
Secondary Toxicity From day 1 of treatment until off study Yes
Secondary Objective response rate Brain imaging to assess tumor response to the treatment is performed at baseline, at the end of courses 2, 4, 6 and at the end of therapy. End of courses 2, 4, 6 and at the end of treatment No
See also
  Status Clinical Trial Phase
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT00006080 - Fenretinide in Treating Patients With Recurrent Malignant Glioma Phase 2
Recruiting NCT00887146 - Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Phase 3
Suspended NCT00935090 - 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer N/A
Completed NCT00621686 - Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme Phase 2
Terminated NCT00227032 - Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme Phase 1
Completed NCT00112502 - Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme Phase 2
Terminated NCT00243022 - Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme Phase 2
Active, not recruiting NCT00087815 - Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain N/A
Active, not recruiting NCT00278278 - Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Phase 3
Completed NCT00416819 - Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma N/A
Completed NCT00052286 - Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer N/A
Completed NCT00006093 - EMD 121974 in Treating Patients With Progressive or Recurrent Glioma Phase 1/Phase 2
Recruiting NCT00004129 - Phosphorus 32 in Treating Patients With Glioblastoma Multiforme Phase 1
Completed NCT00004212 - DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Phase 1
Completed NCT00003417 - Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme Phase 1/Phase 2
Completed NCT00003484 - Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors Phase 1
Completed NCT00003020 - LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases Phase 1
Completed NCT00008008 - Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Phase 2
Completed NCT00003464 - Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme Phase 2